about
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesImmune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosusThe lupus susceptibility locus Sle3 is not sufficient to accelerate atherosclerosis in lupus-susceptible low density lipoprotein receptor-deficient mice.Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosusDyslipidaemia in rheumatological autoimmune diseasesThe reduction of aorta histopathological images through inhibition of reactive oxygen species formation in hypercholesterolemia rattus norvegicus treated with polysaccharide peptide of Ganoderma lucidum.Vasculitis: mechanisms involved and clinical manifestationsAssociation of systemic lupus erythematosus with angiographically defined coronary artery disease: a retrospective cohort study.Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus.Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus.Cardiovascular and disease-related predictors of depression in systemic lupus erythematosus.Psoriasis comorbidities.Development of appropriate coronary heart disease risk prediction models in HIV-infected patients.Apolipoprotein H promoter polymorphisms in relation to lupus and lupus-related phenotypes.Systemic lupus erythematosus and cardiovascular disease.Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosusTranslational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis.Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors.Lethal manifestations of systemic lupus erythematosus in a forensic context.Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages.ApoE-/-Fas-/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia.Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor.Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis.Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus.Adherence with advice and prescriptions in SLE is mostly good, but better follow up is needed: a study with a questionnaire.Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.Visualization of plaque distribution in a curved artery: three-dimensional intravascular ultrasound imaging.Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosusAntihyperlipidemic studies of newly synthesized phenolic derivatives: in silico and in vivo approaches
P2860
Q28388335-337850EB-7E28-4E4B-A4AC-680AF09DD0CBQ28591255-5AF964A3-1B2F-48B9-8238-7881DDA9B960Q33575750-092F685B-6BCD-41D3-8C33-B4C85054864AQ34613997-3FE05A3D-86FB-459B-9F71-9234C5A7D058Q35029916-25C1BF6B-98E8-45E9-8F96-557B275D7EECQ35678292-C94B98F3-2BD4-497C-B3ED-1105706A5054Q36130959-59B60DDA-2203-4B76-806C-86A9CC2E5712Q36395191-BC515FBA-01F9-4DFC-91D4-F928BE5D9CDDQ36611056-E80BCA65-88D4-4842-9E2F-AB899ABF269FQ36951816-D04F7AB1-972A-4430-8B73-BC8560BC11A0Q37019825-75D46EE2-C5F6-4857-9FF0-3A0E80B9443FQ37084274-CEFB0F53-2E97-4F0C-88FE-37F7FB55A7C1Q37111718-E32C0273-FFDF-4B5D-BE3D-EBF37AF0A2E5Q37154155-040E037D-4CC3-43C0-9BEF-1D9B6D65C900Q37167995-8F0F5FD6-4D9C-4A79-9C14-5845CD8DAB5AQ37233045-DBA57C28-A1CA-4E85-9820-9CEED2F9476FQ37421814-F392E4CC-2527-4327-A267-34878A408789Q37425906-D8289391-C102-421A-97AF-48B2FBAF5CB1Q37838467-AC98B2B3-BCB7-4260-AACC-15889016B75FQ40043923-57094386-A0D2-48E9-9A48-8CB3F542E881Q46014277-9163B5E4-0C2B-4A50-8E7F-BBFBF864AE3AQ46920946-6F14BF75-926A-435C-AF4B-503B61DDEE77Q46934492-E7A27203-67C3-4FF6-B1EF-745CF028192DQ46982878-DA87916E-C3F8-40ED-811C-72D8A0BA40E4Q50146708-575CEC92-41CD-485A-84E6-17EE1F12F952Q50571191-EE55FA23-24EB-4B76-9807-ECD409F0907AQ51774455-CCB8B67A-D9C9-4E5E-A04D-6EF041D1FD62Q58190241-9608421B-87BB-496B-B4DF-C6B20C6A1E1BQ58793231-D10F2EE6-35CE-47D5-9ABF-BB938E1989C3
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
SLE, atherosclerosis and cardiovascular disease.
@ast
SLE, atherosclerosis and cardiovascular disease.
@en
type
label
SLE, atherosclerosis and cardiovascular disease.
@ast
SLE, atherosclerosis and cardiovascular disease.
@en
prefLabel
SLE, atherosclerosis and cardiovascular disease.
@ast
SLE, atherosclerosis and cardiovascular disease.
@en
P2860
P1476
SLE, atherosclerosis and cardiovascular disease.
@en
P2093
Frostegård J
P2860
P304
P356
10.1111/J.1365-2796.2005.01502.X
P407
P577
2005-06-01T00:00:00Z